Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Net Income towards Common Stockholders (2020 - 2023)

Historic Net Income towards Common Stockholders for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.5 million.

  • Immuneering's Net Income towards Common Stockholders fell 1543.57% to -$15.5 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$15.5 million, marking a year-over-year increase of 7051.25%. This contributed to the annual value of -$54.8 million for FY2023, which is 849.74% down from last year.
  • According to the latest figures from Q4 2023, Immuneering's Net Income towards Common Stockholders is -$15.5 million, which was down 1543.57% from -$13.1 million recorded in Q3 2023.
  • In the past 5 years, Immuneering's Net Income towards Common Stockholders ranged from a high of -$3.6 million in Q2 2020 and a low of -$15.5 million during Q4 2023
  • In the last 4 years, Immuneering's Net Income towards Common Stockholders had a median value of -$11.5 million in 2022 and averaged -$10.2 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 12162.34% in 2021, then plummeted by 81.48% in 2023.
  • Quarter analysis of 4 years shows Immuneering's Net Income towards Common Stockholders stood at -$5.8 million in 2020, then tumbled by 88.02% to -$11.0 million in 2021, then dropped by 22.75% to -$13.5 million in 2022, then fell by 15.44% to -$15.5 million in 2023.
  • Its Net Income towards Common Stockholders stands at -$15.5 million for Q4 2023, versus -$13.1 million for Q3 2023 and -$12.3 million for Q2 2023.